Emerging high-density lipoprotein infusion therapies: Fulfilling the promise of epidemiology?

Journal of Clinical Lipidology

Volumn 4, Issue 5, 2010, Pages 399-404

  Tardif, Jean Claude ^a,b  

^a MONTREAL HEART INSTITUTE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

ApoA 1 Milano; Atherosclerosis; HDL cholesterol; Intravascular ultrasound

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN A1; CELL ADHESION MOLECULE; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; CSL 111; ETC 216; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIVER ENZYME; NITRIC OXIDE SYNTHASE; PHOSPHATIDYLCHOLINE; RECOMBINANT HIGH DENSITY LIPOPROTEIN; UNCLASSIFIED DRUG;

ACUTE CORONARY SYNDROME; ANGIOCARDIOGRAPHY; ARTERY WALL; ATHEROSCLEROSIS; CHOLESTEROL TRANSPORT; CONFERENCE PAPER; DISEASE COURSE; DRUG EFFICACY; DRUG INFUSION; DRUG SAFETY; HUMAN; INTRAVASCULAR ULTRASOUND; MONOCYTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR ENDOTHELIUM;

ACUTE CORONARY SYNDROME; ANIMALS; APOLIPOPROTEIN A-I; CHOLESTEROL, HDL; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; INFUSIONS, INTRAVENOUS; LIPOPROTEINS, HDL; PHOSPHATIDYLCHOLINES; PILOT PROJECTS; RABBITS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

ANIMALIA; GLYCINE MAX;

EID: 77957884737     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2010.08.018     Document Type: Conference Paper

References (34)

1. D.J. Gordon, J.L. Probstfield, and R.J. Garrison High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies Circulation 79 1989 8 15
2. P.J. Barter, M. Caulfield, and M. Eriksson ILLUMINATE Investigators: effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 2007 2109 2122
3. G. Schmitz, and M. Grandl Vesicular trafficking mechanisms to mediate cellular lipid homeostasis Arterioscler Thromb Vasc Biol 29 2009 1718 1722
4. L. Calabresi, M. Gomaraschi, and G. Franceschini Endothelial protection by high-density lipoproteins. From bench to bedside Arterioscler Thromb Vasc Biol 23 2003 1724 1731
5. A.M. Zeiher, V. Schachlinger, S.H. Hohnloser, B. Saurbier, and H. Just Coronary atherosclerotic wall thickening and vascular reactivity in humans: elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis Circulation 89 1994 2525 2532
6. L.E. Spieker, I. Sudano, and D. Hurlimann High-density lipoprotein restores endothelial function in hypercholesterolemic men Circulation 105 2002 1399 1402
7. G. Murugesan, G. Sa, and P.L. Fox High-density lipoprotein stimulates endothelial cell movement by a mechanism distinct from basic fibroblast growth factor Circ Res 74 1994 1149 1156
8. M. Sugano, K. Tsuchida, and N. Makino High-density lipoprotein protects endothelial cells from tumor necrosis factor-alpha-induced apoptosis Biochem Biophys Res Commun 272 2000 872 876
9. P.J. Barter, P.W. Baker, and K.A. Rye Effect of high-density lipoprotein on the expression of adhesion molecules in endothelial cells Curr Opin Lipidol 13 2002 285 288
10. G. Theilmeier, B. De Geest, and P.P. Van Veldhoven HDL-associated PAF-AH reduces endothelial adhesiveness in apoE-/- mice FASEB J 14 2000 2032 2039
11. L. Calabresi, M. Gomaraschi, B. Villa, L. Omoboni, C. Dmitrieff, and G. Franceschini Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol Arterioscler Thromb Vasc Biol 22 2002 656 661
12. M.G. Conlan, A.R. Folsom, and A. Finch Associations of factor VIII and von Willebrand factor with age, race, sex, and risk factors for atherosclerosis: the Atherosclerosis Risk in Communities (ARIC) Study Thromb Haemost 70 1993 380 385
13. T.Z. Naqvi, P.K. Shah, and P.A. Ivey Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation Am J Cardiol 84 1999 1011 1017
14. M. Navab, J.A. Berliner, and G. Subbanagounder HDL and the inflammatory response induced by LDL-derived oxidized phospholipids Arterioscler Thromb Vasc Biol 21 2001 481 488
15. J.J. Badimon, L. Badimon, A. Galvez, R. Dische, and V. Fuster High density lipoprotein plasma fraction inhibits fatty streaks in cholesterol-fed rabbits Lab Invest 60 1989 455 461
16. J.J. Badimon, L. Badimon, and V. Fuster Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit J Clin Invest 85 1990 1234 1241
17. A. Miyazaki, S. Sakuma, and W. Morikawa Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits Arterioscler Thromb Vasc Biol 15 1995 1882 1888
18. S. Ameli, A. Hultgardh-Nilsson, and B. Cercek Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits Circulation 90 1994 1935 1941
19. M.R. Soma, E. Donetti, C. Parolini, C.R. Sirtori, R. Fumagalli, and G. Franceschini Recombinant apolipoprotein A-I Milano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits Circ Res 76 1995 405 411
20. P.K. Shah, J. Nilsson, and S. Kaul Effects of recombinant apolipoprotein A-I Milano on aortic atherosclerosis in apolipoprotein E-deficient mice Circulation 97 1998 780 785
21. P.K. Shah, J. Yano, and O. Reyes High-dose recombinant apolipoprotein A-I Milano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein E-deficient mice. Potential implications for acute plaque stabilization Circulation 103 2001 3047 3050
22. G. Chiesa, E. Monteggia, and M. Marchesi Recombinant apolipoprotein A-I Milano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks Circ Res 90 2002 974 980
23. S. Kaul, B. Coin, and A. Hedayiti Rapid reversal of endothelial dysfunction in hypercholesterolemic apolipoprotein E-null mice by recombinant apolipoprotein A-1(Milano)-phospholipid complex J Am Coll Cardiol 44 2004 1311 1319
24. M. Eriksson, L.A. Carlson, T.A. Mietinnen, and B. Angelin Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I: potential reverse cholesterol transport in humans Circulation 100 1999 594 598
25. M.N. Nanjee, C.J. Cooke, and R. Garvin Intravenous apo A-1/lecithin discs increase pre-beta HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans J Lipid Res 42 2001 1586 1593
26. T. Kujiraoka, M.N. Nanjee, and T. Oka Effects of intravenous apolipoprotein A-I phosphatidyl choline discs on LCAT, PLTP, and CETP in plasma and peripheral lymph in humans Arterioscler Thromb Vasc Biol 23 2003 1653 1659
27. S.E. Nissen, T. Tsunoda, and E.M. Tuzcu Effect of recombinant ApoA-1 Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial JAMA 290 2003 2292 2300
28. CNN.com. Pfizer to buy Esperion for $1.6 bn, December 21, 2003. Available at: http://www.cnn.com/2003/BUSINESS/12/21/us.pfizer.reut/. Accessed August 24, 2010.
29. United States Securities and Exchange Commission filing. Available at: http://www.faqs.org/sec-filings/091224/MEDICINES-CO-DE-8-K. Accessed August 24, 2010.
30. J.C. Tardif, J. Grégoire, and P.L. L'Allier Effect of rHDL on Atherosclerosis-Safety and Efficacy (ERASE) Investigators: effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial JAMA 297 2007 1675 1682
31. D. Waters, T.E. Craven, and J. Lespérance Prognostic significance of progression of coronary atherosclerosis Circulation 87 1993 1067 1075
32. Safety, tolerability and pharmacokinetics of CSL 112 in healthy volunteers. Clinicaltrials.gov #NCT01129661. Available at: http:// clinicaltrials.gov/ct2/show/NCT011296611. Accessed August 24, 2010.
33. R. Wakesman, R. Torguson, and K.M. Kent A first-in-man, randomized, placebo-controlled study to evaluate the safety and feasibility of autologous delipidated high-density lipoprotein plasma infusions in patients with acute coronary syndrome J Am Coll Cardiol 55 2010 2727 2735
34. Cerenis Therapeutics completes CER-001 phase 1 study. Available at: http://clinicaltrials.pharmaceutical-business-review.com/news/ cerenis-therapeutics-completes-cer001-phase-1-study-100518/. Accessed August 24, 2010.